-
Mashup Score: 0COVID‐19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)‐T‐cell therapy - 7 month(s) ago
More than 3 years have passed since Coronavirus disease 2019 (COVID-19) was declared a global pandemic, yet COVID-19 still severely impacts immunocompromised individuals including those treated with…
Source: onlinelibrary.wiley.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0article - 8 month(s) ago
NewsOncology Times45(8):p 17-18, April 20, 2023. | DOI: 10.1097/01.COT.0000932012.82499.42Next-Generation Cell TherapiesNext-Generation Cell TherapiesThe Friends of Cancer Research (Friends) held a webinar to update progress on its project aimed at accelerating the development of engineered cell therapies for cancer patients. Jeff Allen, PhD, President and CEO of Friends, said the organization…
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Engineering immunosuppressive drug-resistant armored (IDRA) SARS-CoV-2 T cells for cell therapy - 8 month(s) ago
Cellular & Molecular Immunology – Engineering immunosuppressive drug-resistant armored (IDRA) SARS-CoV-2 T cells for cell therapy
Source: www.nature.comCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 0Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study - 8 month(s) ago
In the single-arm, open-label, multicenter, phase 2 PILOT study, second-line treatment with the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) for whom hematopoietic stem cell transplantation (HSCT) was not intended resulted in high response rates, durable responses, and a safety profile consistent with previous reports. Here, we analyzed changes in health-related quality of life (HRQOL) in patients who received liso-cel in PILOT. Patients received liso-cel, an autologous, CD19-directed, 4-1BB CAR T-cell product administered at equal target doses of CD8+ and CD4+ CAR+ T cells, for a total target dose of 100 × 10⁶ CAR+ T cells. HRQOL, a secondary endpoint of PILOT, was assessed as prespecified using 3 patient-reported outcome instruments (EORTC QLQ-C30; FACT-LymS; EQ-5D-5L). Evaluable datasets for the EORTC QLQ-C30, FACT-LymS, EQ-5D-5L health utility index, and EQ-5D visual ana
Source: haematologica.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0ACCESS Initiative - 8 month(s) ago
The American Society for Transplantation and Cellular Therapy is an international professional membership association of more than 3,600 physicians, investigators and other health care professionals from more than 45 countries. Our mission is dedicated to improving the application and success of blood and marrow transplantation and related cellular therapies. We strive to be the leading organization promoting research, education and clinical practice in the field.
Source: www.astct.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1CD19-CAR T-Cell Therapy Demonstrates Activity Against Extramedullary Disease in Pediatric Patients with B-ALL - 9 month(s) ago
Key Points. There is a high burden of extramedullary disease in pediatric patients with relapsed/refractory B-ALL prior to CD19-CAR T cell therapyCD19-CAR T cel
Source: ashpublications.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions - 9 month(s) ago
Key Points. In this analysis, checkpoint inhibitor therapy after CAR-T failure resulted in an overall response rate of 19% and median PFS of 54 days.Patients wi
Source: ashpublications.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 4Emapalumab for the treatment of Refractory Cytokine Release Syndrome in Pediatric Patients - 9 month(s) ago
Emapalumab is a monoclonal antibody targeting interferon gamma (IFN-g) and is currently FDA-approved for refractory, recurrent, or progressive hemophagocytic ly
Source: ashpublications.orgCategories: Hematologists1, Latest HeadlinesTweet-
RT @CARTTherapy: Emapalumab for the treatment of Refractory Cytokine Release Syndrome in Pediatric Patients https://t.co/CU2I3YVz5g #CART…
-
-
Mashup Score: 1
Abstract. Patients with cancer demonstrate an increased vulnerability for infection and severe disease by SARS-CoV-2, the causative agent of COVID-19. Risk fact
Source: academic.oup.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Longitudinal Serum Proteomics Characterization of CD19-CAR-T Cell Therapy for B-Cell Malignancies - 9 month(s) ago
Chimeric antigen receptor (CAR)-modified T cells have demonstrated remarkable efficacy in treating B-cell leukemia. However, treated patients may potentially develop side effects, such as cytokine release syndrome (CRS), the mechanisms of which remain unclear. Here, we collected 43 serum samples from eight patients with B-cell acute lymphoblastic leukemia (B-ALL) before and five time points after CD19-specific CAR-T cell treatment. Using TMTpro 16-plex-based quantitative proteomics, we quantified 1151 proteins and profiled the longitudinal proteomes analysis of each patient. Seven days after therapy, we found the most dysregulated inflammatory proteins. Lipid metabolism proteins, including APOA1, decreased after therapy, reached their minimum after 7 days, and then gradually recovered. Hence, APOA1 has been selected as a potential biomarker of the CRS disease progression. Furthermore, we identified CD163 as a potential biomarker of CRS severity. These two biomarkers were successfully v
Source: pubs.acs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
COVID‐19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)‐T‐cell therapy - Kampouri -#CART #bmtsm #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy @ASTCT @CART_Therapy https://t.co/k8fdrErKne